China Biotechs See Manufacturing Disruption As Cases Hit Suzhou
Shanghai Lockdown GDP Impact
Executive Summary
As Shanghai's COVID-19 outbreak and lockdowns continue, neighboring biotech cluster Suzhou is now imposing restrictions, with firms there expecting large disruptions to manufacturing and clinical study halts amid few signs of easing in China's "COVID Zero" policies.
You may also be interested in...
USP Exec On Onshoring, Impact Of War-Fueled Metals Turbulence On Pharma
US Pharmacopeia senior director, regional program operations, South Asia, Matruprasad Priyadarshi, discusses with Scrip the need to assess onshoring on a medicine-by-medicine basis and the organization’s efforts to support quality assessments for new mRNA-based therapies. The executive also flags up new trouble spots as metals such as aluminium and nickel, used in medical products and currently witnessing price surges, are mined in the war-torn Russia-Ukraine region.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.